Sapphire Star Partners LP Has $3.47 Million Position in Amgen, Inc. (NASDAQ:AMGN)

Sapphire Star Partners LP lowered its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,840 shares of the medical research company’s stock after selling 586 shares during the period. Amgen accounts for 4.6% of Sapphire Star Partners LP’s investment portfolio, making the stock its 2nd biggest holding. Sapphire Star Partners LP’s holdings in Amgen were worth $3,473,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of AMGN. Annex Advisory Services LLC increased its position in shares of Amgen by 7.2% in the fourth quarter. Annex Advisory Services LLC now owns 10,157 shares of the medical research company’s stock valued at $1,977,000 after acquiring an additional 678 shares during the period. Premier Fund Managers Ltd boosted its stake in Amgen by 11.6% during the fourth quarter. Premier Fund Managers Ltd now owns 25,141 shares of the medical research company’s stock worth $4,795,000 after acquiring an additional 2,608 shares in the last quarter. Bahl & Gaynor Inc. boosted its stake in Amgen by 41.6% during the fourth quarter. Bahl & Gaynor Inc. now owns 1,336,055 shares of the medical research company’s stock worth $260,089,000 after acquiring an additional 392,493 shares in the last quarter. Penobscot Investment Management Company Inc. boosted its stake in Amgen by 2.9% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 28,636 shares of the medical research company’s stock worth $5,574,000 after acquiring an additional 810 shares in the last quarter. Finally, Sarasin & Partners LLP boosted its stake in Amgen by 0.8% during the fourth quarter. Sarasin & Partners LLP now owns 862,892 shares of the medical research company’s stock worth $167,979,000 after acquiring an additional 6,960 shares in the last quarter. Institutional investors own 80.04% of the company’s stock.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the transaction, the director now owns 14,988 shares in the company, valued at $2,830,933.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by company insiders.

Shares of NASDAQ AMGN traded up $0.99 during midday trading on Friday, reaching $181.47. The stock had a trading volume of 2,345,291 shares, compared to its average volume of 3,026,303. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57. The stock has a market cap of $110.72 billion, a PE ratio of 12.60, a price-to-earnings-growth ratio of 2.22 and a beta of 1.21. Amgen, Inc. has a 12-month low of $165.22 and a 12-month high of $210.19.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. During the same period in the prior year, the company posted $2.89 earnings per share. On average, research analysts expect that Amgen, Inc. will post 13.82 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s dividend payout ratio is 40.28%.

AMGN has been the topic of several research reports. Cowen reissued a “buy” rating and set a $234.00 price objective on shares of Amgen in a research note on Tuesday, February 26th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, January 14th. Goldman Sachs Group reiterated a “buy” rating and issued a $232.00 target price on shares of Amgen in a research note on Thursday, January 17th. Mizuho reiterated a “buy” rating and issued a $211.00 target price on shares of Amgen in a research note on Wednesday, February 13th. Finally, BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 29th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $209.11.

WARNING: This story was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/sapphire-star-partners-lp-has-3-47-million-holdings-in-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.